Company intelligence / Profile preview

Karcinolys

Paris, France

Ownership: Private
Development stage: Other

Overview

Myb34.5 oncolytic virus showed preclinical efficacy in pancreatic cancer models with orphan drug designations from FDA (Dec 2014) and EMA (Jan 2015). First-in-human trials planned for end of H2 2016.[1]

Therapeutic areas: Oncology
Modalities: Oncolytic virus
Industry: Biotech

Beyond the preview

Go deeper on Karcinolys.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Karcinolys.

Explore the full profile